伊利巴西班标准品 | 536748-46-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 伊利巴西班标准品
• 英文名称: Eribaxaban
• 英文别名: (2R,4R)-N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-1,2-pyrrolidinedicarboxamide；(2R,4R)-4-methoxy-pyrrolidine-1,2-dicarboxylic acid 1-[(4-chloro-phenyl)-amide]-2-{[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenyl]-amide}；(2R,4R)-1-N-(4-chlorophenyl)-2-N-[2-fluoro-4-(2-oxopyridin-1-yl)phenyl]-4-methoxypyrrolidine-1,2-dicarboxamide
• CAS: 536748-46-6
• 化学式: C₂₄H₂₂ClFN₄O₄
• 分子量: 484.914
• InChiKey: QQBKAVAGLMGMHI-WIYYLYMNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  34
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  91
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  (2R,4R)-4-methoxy-pyrrolidine-2-carboxylic acid [2-fluoro-4-(2-oxo-pyridin-1-yl)-phenyl]-amide hydrochloride 、 对氯苯异氰酸酯 在 三乙胺 作用下， 以 乙酸乙酯 、 乙腈 为溶剂， 反应 3.5h， 生成 伊利巴西班标准品
  参考文献：
  名称：

  WO2006/100565

  摘要：

  公开号：

文献信息

• Inhibitors of fractor Xa and other serine proteases involved in the coagulation cascade
  申请人：Bigge Franklin Christopher

  公开号：US20050250815A1

  公开（公告）日：2005-11-10

  The present invention provides compounds of Formula (I): wherein A, B, C, G, and W 1 have any of the values defined in the specification, and pharmaceutically acceptable salt thereof, that are useful to treat thrombotic disorders. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula I, processes for preparing compounds of Formula I, and intermediates useful for preparing compounds of Formula I.

  本发明提供了公式（I）的化合物：其中A，B，C，G和W1具有规范中定义的任何值，并且其药学上可接受的盐，用于治疗血栓性疾病。还披露了包含一个或多个公式I化合物的制药组合物，用于制备公式I化合物的过程以及用于制备公式I化合物的中间体。
• Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
  申请人：Edmunds John Jeremy

  公开号：US20050267118A1

  公开（公告）日：2005-12-01

  The present invention provides compounds of Formula (I): wherein A, B, C, G, and W 1 have any of the values defined in the specification, and pharmaceutically acceptable salt thereof, that are useful to treat thrombotic disorders. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula I, processes for preparing compounds of Formula I, and intermediates useful for preparing compounds of Formula I.

  本发明提供了式（I）的化合物： 其中A、B、C、G和W1具有规范中定义的任何值，以及其药学上可接受的盐，用于治疗血栓性疾病。还公开了包含一个或多个式I化合物的制药组合物，用于制备式I化合物的过程以及制备式I化合物有用的中间体。
• Carbonyl compounds
  申请人：Tsaklakidis Christos

  公开号：US20060183739A1

  公开（公告）日：2006-08-17

  Novel compounds of the formula (I), in which D, E, G, W, X, Y, T, R 1 and R 2 are as defined in Patent Claim 1, are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumours.

  公式（I）的新化合物，其中D，E，G，W，X，Y，T，R1和R2如专利权要求书1所定义，是凝血因子Xa的抑制剂，可用于预防和/或治疗血栓栓塞病和肿瘤治疗。
• INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE
  申请人：Bigge Christopher Franklin

  公开号：US20090221546A1

  公开（公告）日：2009-09-03

  Compounds useful as intermediates for synthesis of compounds of Formula (1): wherein A, B, C, G, and W 1 have any of the values defined in the specification.

  本发明提供的化合物可作为合成式（1）化合物的中间体，其中A、B、C、G和W1的任意值均在规范中定义。
• Factor Xa Inhibitor Crystalline Forms
  申请人：Samas Brian

  公开号：US20080194643A1

  公开（公告）日：2008-08-14

  Disclosed are crystalline forms A, B and C of 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)-(9Cl). These crystalline forms are characterized by their powder X-ray diffraction, solid-state NMR, as well as methods for the preparation and pharmaceutical compositions of the same which are useful for the treatment of acute, subacute, or chronic thrombotic disorders including treatment of venous thrombosis, arterial thrombosis, pulmonary embolism, myocardial infarction, cerebral infarction, restenosis, atherosclerosis, angina, primary and secondary deep vein thrombosis, thromboembolism associated with cardiovascular disease, including, but not limited to, acute coronary syndrome, atrial fibrillation, cardiac valve replacement and deep vein thrombosis. The crystalline forms of the present invention are also useful for the treatment of cancer, sepsis and diabetes.

  本发明涉及1,2-吡咯烷二甲酰胺，N1-(4-氯苯基)-N2-[2-氟-4-(2-氧代-1(2H)-吡啶基)苯基]-4-甲氧基，(2R,4R)-(9Cl)的晶体形式A、B和C。这些晶体形式的特征是它们的粉末X射线衍射，固态核磁共振，以及制备方法和制备的药物组合物，可用于治疗急性、亚急性或慢性血栓性疾病，包括静脉血栓形成、动脉血栓形成、肺栓塞、心肌梗死、脑梗死、再狭窄、动脉粥样硬化、心绞痛、原发性和继发性深静脉血栓形成、与心血管疾病相关的血栓栓塞，包括但不限于急性冠状动脉综合征、心房颤动、心脏瓣膜置换和深静脉血栓形成。本发明的晶体形式还可用于治疗癌症、败血症和糖尿病。